Pregnancy complications are linked to greater health-related social needs among Black and Latina women, a study has found.

Adverse pregnancy outcomes include pre-eclampsia, gestational hypertension, gestational diabetes, low birth weight and preterm birth.

These complications are associated with risks of further complications, chronic disease and cardiovascular disease, and disproportionately affect Black and Latina women.

Researchers from Mass General Brigham found that adverse pregnancy outcomes among Black and Latina women were also associated with substantially greater health-related social needs.

These included education, transport, food security, financial strain, employment and social support.

The researchers said integrating assessments of social needs into postpartum care could help improve long-term maternal health and reduce disparities.

Michael C. Honigberg, cardiologist and researcher with the Mass General Brigham Heart and Vascular Institute and senior author, said: “Pregnancy can offer a critical window of engagement for patients and providers.

“Pregnancy complications should be viewed as an opportunity not only for cardiovascular risk prevention but also for screening for and addressing social needs.”

Honigberg and colleagues from Mass General Brigham’s Heart and Vascular Institute and Department of Obstetrics and Gynecology analysed data from the BUSY-BP cohort study.

The study included Black and Latina women recruited from hospitals and health centres affiliated with Mass General Brigham.

Participants completed a screening tool covering their living situation, food, transport, utilities, safety, financial strain, employment, family and community support, education and other needs.

The study included 883 women who had previously been pregnant, including 400 participants, or 45.3 per cent, who had experienced one or more adverse pregnancy outcomes.

Researchers found that the rate of adverse pregnancy outcomes increased as the burden of health-related social needs rose, particularly for needs related to education.

These included help with starting or completing job training, gaining a high school diploma or obtaining a General Educational Development equivalency certificate.

The authors said further research is needed to separate cause and effect and identify interventions based on the findings that could improve health outcomes.

Honigberg said: “Identifying and testing interventions, such as social support programmes that can help women during the postpartum period, will be critical for improving downstream health outcomes for women and babies.”

Phthalates found in plastics and personal care products may be linked to higher blood pressure during pregnancy, a study suggests.

Hypertensive disorders of pregnancy, including pre-eclampsia, are a leading cause of maternal mortality in the US.

Higher blood pressure during pregnancy has also been linked to adverse health outcomes for both mothers and children.

While family history and lifestyle are known risk factors, growing evidence suggests exposure to phthalates may also contribute to raised blood pressure during pregnancy.

Phthalates are chemicals found in plastics, personal care products and hundreds of other consumer goods. Some can interfere with the body’s natural hormones.

Kimberly Parra, of Harvard T.H. Chan School of Public Health, said: “Our study suggests that having higher concentrations of personal care products-associated chemicals, known as phthalates, in the body might contribute to elevated blood pressure in pregnancy.

“While our study does not show that phthalates cause high blood pressure during pregnancy, it suggests that reducing exposure to this class of chemicals by limiting personal care products containing these ingredients, particularly those with fragrance, may be a way to address high blood pressure in pregnancy and improve pregnancy health.”

Researchers measured phthalate exposure and blood pressure in 338 pregnant women from the Environmental Reproductive and Glucose Outcomes Study at three points during pregnancy.

They analysed whether higher levels of the chemicals, individually and in combination, were linked to higher blood pressure or an increased risk of pregnancy-related high blood pressure disorders.

Women with higher urine concentrations of phthalates associated with fragrances and personal care products had higher systolic and diastolic blood pressure, markers of increased risk of hypertensive disorders of pregnancy.

Systolic blood pressure is the pressure in the arteries when the heart beats, while diastolic pressure measures it between beats.

Around 13 per cent of participants developed a pregnancy-related high blood pressure disorder.

Women with higher levels of certain phthalates, particularly those found in personal care products, tended to have higher blood pressure later in pregnancy.

Parra said: “More research is needed to better understand these findings, particularly whether the effects are driven by changes in oestrogen-related pathways. Additional studies should also examine the potential role of other phthalates and their replacement chemicals.”

Glaucoma drugs could potentially be repurposed to treat aggressive breast cancer after researchers identified markers linked to response.

Scientists found that several cancers, including breast cancer, melanoma and a type of blood cancer, rely on the same molecule to become aggressive and spread.

Drugs that block the molecule are already used to treat glaucoma and may therefore have potential as cancer treatments.

Researchers also identified markers that could help indicate which patients may respond well to the drugs.

Experts said the findings could help establish which patients may benefit from existing treatments.

Repurposing medicines already shown to be safe could also allow treatments to reach patients faster.

Lead author Victoria Sanz Moreno, professor of cancer cell and metastasis biology at The Institute of Cancer Research in London, said: “Some cancers are particularly aggressive, and once they spread they become very hard to treat.

“Catching these aggressive cancers and preventing their ability to move around the body is really crucial to our mission to keep more people living well with cancer.

“Our research has identified a shared weakness of aggressive cancer cells that could be targeted across many cancer types, wherever they originate in the body.

“We confirmed our findings in aggressive cancers such as breast cancer, melanoma, and a type of blood cancer called acute myeloid leukaemia, but we believe this molecular fingerprint of cancer cells likely to die after treatment applies to many more cancer types.

“It’s reassuring to know that a treatment already exists – a drug currently being used safely in some patients could be adapted to treat these cancers.”

Researchers set out to find markers that could identify which cancers would respond well to drugs blocking ROCK, also known as Rho kinase.

Aggressive cancer cells rely on ROCK as they spread around the body and cause advanced disease that is harder to treat.

The molecule keeps the scaffolding inside cells tense, causing them to contract and become round and generating enough force for cancer cells to squeeze through tissue.

The team, working in the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, examined data from a drug-sensitivity database to identify which cancer cells responded to ROCK inhibitors.

Breast cancer cells that responded to ROCK inhibitors had a particular gene called E-Cadherin that was not working properly.

In melanoma, responsive cells tended to have a more rounded shape and high activity in a signalling pathway called NFKB.

Acute myeloid leukaemia cells that responded well to ROCK inhibitors had a specific subset of genetic alterations.

Researchers then tested the findings in laboratory tumour samples and mouse studies.

They hope tumour biopsies showing these markers could eventually help identify patients who may respond well to ROCK inhibitors.

Dr Simon Vincent, chief scientific officer at Breast Cancer Now, said: “With around 11,500 women tragically dying from breast cancer every year in the UK, research like this is vital to finding more effective treatment options.

“This study helps to lay the foundation for understanding who among those with certain cancers, including breast cancer, might benefit most from existing drugs. Finding new uses for existing treatments, which we know people can safely take, is easier and faster than developing new cancer drugs from scratch.

“It’s encouraging that these drugs may be especially effective in targeting cancer cells that are more likely to spread and resist treatment.

“While this research is still at an early stage and clinical trials are needed, it’s an important step towards more personalised breast cancer treatments in the future.”

First author Jaume Barcelo, formerly a postdoctoral research fellow at The Institute of Cancer Research in London and now based at Barts Cancer Institute at Queen Mary University of London, said: “Our study has identified a specific pattern of features that is consistent across many cancer types, and that can be used to match the right patients to this treatment.

“The next stage for this research will be to test how these drugs that inhibit ROCK work in combination with other treatments, to maximise the benefit for patients.

“As ROCK inhibitors are already approved to treat glaucoma, I hope that our findings can be used to progress the drugs into clinical trials to treat cancer in the near future.”

The research was funded by The Institute of Cancer Research, Breast Cancer Now, Barts Cancer Charity, Cancer Research UK, Worldwide Cancer Research and UK Research and Innovation.

Susanna Daniels, chief executive officer of Melanoma Focus, said: “Despite major advances in melanoma treatment over the past decade, too many people still die from the disease each year, and not every patient responds to the treatments currently available.

“Every new discovery improves our understanding of how melanoma grows and survives, bringing us closer to treatments that are more effective, more targeted and have the potential to improve survival.

“While these findings are still at an early stage and will need to be tested in clinical trials, they offer an encouraging direction for future melanoma research and the development of more personalised treatments.”